Abstract
Most of the current drugs used to treat cancer can be classified as anti-proliferative drugs. These drugs perturb the proliferative cycle of tumor cells at diverse stages of the cell cycle. Examples of such drugs are DNA-damaging agents and inhibitors of cyclin-dependent kinases that arrest cell cycle progression at different stages of interphase. Another class of anti-proliferative drugs is the so-called anti-mitotic drugs, which selectively perturb progression through mitosis. Mitosis is the shortest and final stage in the cell cycle and has evolved to accurately divide the duplicated genome over the two daughter cells. This review deals with the different strategies that are currently considered to perturb mitotic progression in the treatment of cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Allan LA, Clarke PR . (2007). Phosphorylation of caspase-9 by CDK1/cyclin B1 protects mitotic cells against apoptosis. Mol Cell 26: 301–310.
Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S et al. (2004). Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 279: 25549–25561.
Andreassen PR, Lohez OD, Lacroix FB, Margolis RL . (2001). Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1. Mol Biol Cell 12: 1315–1328.
Baker DJ, Jin F, Jeganathan KB, van Deursen JM . (2009). Whole chromosome instability caused by Bub1 insufficiency drives tumorigenesis through tumor suppressor gene loss of heterozygosity. Cancer Cell 16: 475–486.
Barber TD, McManus K, Yuen KW, Reis M, Parmigiani G, Shen D et al. (2008). Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers. Proc Natl Acad Sci USA 105: 3443–3448.
Barr FA, Gruneberg U . (2007). Cytokinesis: placing and making the final cut. Cell 131: 847–860.
Barr FA, Sillje HH, Nigg EA . (2004). Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 5: 429–440.
Basto R, Brunk K, Vinadogrova T, Peel N, Franz A, Khodjakov A et al. (2008). Centrosome amplification can initiate tumorigenesis in flies. Cell 133: 1032–1042.
Blangy A, Lane HA, d'Herin P, Harper M, Kress M, Nigg EA . (1995). Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 83: 1159–1169.
Boveri T . (1914). Zur Frage der Entstehung maligner Tumoren. Gustav Fischer: Jena, vol. 1.
Brier S, Lemaire D, DeBonis S, Forest E, Kozielski F . (2006). Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents. J Mol Biol 360: 360–376.
Brinkley BR . (2001). Managing the centrosome numbers game: from chaos to stability in cancer cell division. Trends Cell Biol 11: 18–21.
Brito DA, Rieder CL . (2006). Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr Biol 16: 1194–1200.
Brito DA, Rieder CL . (2009). The ability to survive mitosis in the presence of microtubule poisons differs significantly between human nontransformed (RPE-1) and cancer (U2OS, HeLa) cells. Cell Motil Cytoskeleton 66: 437–447.
Buffin E, Emre D, Karess RE . (2007). Flies without a spindle checkpoint. Nat Cell Biol 9: 565–572.
Carmena M, Earnshaw WC . (2003). The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 4: 842–854.
Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z . (2006). A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38: 1043–1048.
Cohen J . (2002). Sorting out chromosome errors. Science 296: 2164–2166.
Colombo R, Caldarelli M, Mennecozzi M, Giorgini ML, Sola F, Cappella P et al. (2010). Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase. Cancer Res 70: 10255–10264.
Cox CD, Coleman PJ, Breslin MJ, Whitman DB, Garbaccio RM, Fraley ME et al. (2008). Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2- (hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer. J Med Chem 51: 4239–4252.
D'Assoro AB, Barrett SL, Folk C, Negron VC, Boeneman K, Busby R et al. (2002a). Amplified centrosomes in breast cancer: a potential indicator of tumor aggressiveness. Breast Cancer Res Treat 75: 25–34.
D'Assoro AB, Lingle WL, Salisbury JL . (2002b). Centrosome amplification and the development of cancer. Oncogene 21: 6146–6153.
Degenhardt Y, Lampkin T . (2010). Targeting Polo-like kinase in cancer therapy. Clin Cancer Res 16: 384–389.
Ditchfield C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T et al. (2003). Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 161: 267–280.
Doxsey S . (2001). Re-evaluating centrosome function. Nat Rev Mol Cell Biol 2: 688–698.
Duesberg P, Li R, Rasnick D, Rausch C, Willer A, Kraemer A et al. (2000). Aneuploidy precedes and segregates with chemical carcinogenesis. Cancer Genet Cytogenet 119: 83–93.
Fujiwara T, Bandi M, Nitta M, Ivanova EV, Bronson RT, Pellman D . (2005). Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 437: 1043–1047.
Fukasawa K . (2007). Oncogenes and tumour suppressors take on centrosomes. Nat Rev Cancer 7: 911–924.
Galipeau PC, Cowan DS, Sanchez CA, Barrett MT, Emond MJ, Levine DS et al. (1996). 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci USA 93: 7081–7084.
Ganem NJ, Godinho SA, Pellman D . (2009). A mechanism linking extra centrosomes to chromosomal instability. Nature 460: 278–282.
Ganem NJ, Pellman D . (2007). Limiting the proliferation of polyploid cells. Cell 131: 437–440.
Ganem NJ, Storchova Z, Pellman D . (2007). Tetraploidy, aneuploidy and cancer. Curr Opin Genet Dev 17: 157–162.
Gascoigne KE, Taylor SS . (2008). Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14: 111–122.
Godinho SA, Kwon M, Pellman D . (2009). Centrosomes and cancer: how cancer cells divide with too many centrosomes. Cancer Metastasis Rev 28: 85–98.
Goodin S . (2008). Novel cytotoxic agents: epothilones. Am J Health Syst Pharm 65: S10–S15.
Gumireddy K, Reddy MV, Cosenza SC, Boominathan R, Baker SJ, Papathi N et al. (2005). ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7: 275–286.
Guo Z, Kozlov S, Lavin MF, Person MD, Paull TT . (2010). ATM activation by oxidative stress. Science 330: 517–521.
Ha GH, Baek KH, Kim HS, Jeong SJ, Kim CM, McKeon F et al. (2007). p53 activation in response to mitotic spindle damage requires signaling via BubR1-mediated phosphorylation. Cancer Res 67: 7155–7164.
Hanks S, Coleman K, Reid S, Plaja A, Firth H, Fitzpatrick D et al. (2004). Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. Nat Genet 36: 1159–1161.
Harley ME, Allan LA, Sanderson HS, Clarke PR . (2010). Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J 29: 2407–2420.
Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T et al. (2004). VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10: 262–267.
Harrison MR, Holen KD, Liu G . (2009). Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. Clin Adv Hematol Oncol 7: 54–64.
Hauf S, Cole RW, LaTerra S, Zimmer C, Schnapp G, Walter R et al. (2003). The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 161: 281–294.
Holland AJ, Cleveland DW . (2009). Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nat Rev Mol Cell Biol 10: 478–487.
Huang HC, Shi J, Orth JD, Mitchison TJ . (2009). Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. Cancer Cell 16: 347–358.
Huszar D, Theoclitou ME, Skolnik J, Herbst R . (2009). Kinesin motor proteins as targets for cancer therapy. Cancer Metastasis Rev 28: 197–208.
Janssen A, Kops GJ, Medema RH . (2009). Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. Proc Natl Acad Sci USA 106: 19108–19113.
Jordan MA, Thrower D, Wilson L . (1991). Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res 51: 2212–2222.
Jordan MA, Toso RJ, Thrower D, Wilson L . (1993). Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90: 9552–9556.
Jordan MA, Wilson L . (2004). Microtubules as a target for anticancer drugs. Nat Rev Cancer 4: 253–265.
Kaestner P, Stolz A, Bastians H . (2009). Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells. Mol Cancer Ther 8: 2046–2056.
Kaitna S, Mendoza M, Jantsch-Plunger V, Glotzer M . (2000). Incenp and an aurora-like kinase form a complex essential for chromosome segregation and efficient completion of cytokinesis. Curr Biol 10: 1172–1181.
Kapoor TM, Mayer TU, Coughlin ML, Mitchison TJ . (2000). Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. J Cell Biol 150: 975–988.
Keen N, Taylor S . (2009). Mitotic drivers—inhibitors of the aurora B kinase. Cancer Metastasis Rev 28: 185–195.
Khodjakov A, Rieder CL, Sluder G, Cassels G, Sibon O, Wang CL . (2002). De novo formation of centrosomes in vertebrate cells arrested during S phase. J Cell Biol 158: 1171–1181.
Kitzen JJ, de Jonge MJ, Verweij J . (2010). Aurora kinase inhibitors. Crit Rev Oncol Hematol 73: 99–110.
Kops GJ . (2008). The kinetochore and spindle checkpoint in mammals. Front Biosci 13: 3606–3620.
Kops GJ, Foltz DR, Cleveland DW . (2004). Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci USA 101: 8699–8704.
Kops GJ, Weaver BA, Cleveland DW . (2005). On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 5: 773–785.
Kwiatkowski N, Jelluma N, Filippakopoulos P, Soundararajan M, Manak MS, Kwon M et al. (2010). Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. Nat Chem Biol 6: 359–368.
Kwon M, Godinho SA, Chandhok NS, Ganem NJ, Azioune A, Thery M et al. (2008). Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes. Genes Dev 22: 2189–2203.
Lengauer C, Kinzler KW, Vogelstein B . (1997). Genetic instability in colorectal cancers. Nature 386: 623–627.
Lens SM, Voest EE, Medema RH . (2010). Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 10: 825–841.
LeRoy PJ, Hunter JJ, Hoar KM, Burke KE, Shinde V, Ruan J et al. (2007). Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A: a novel pharmacodynamic method for measuring Aurora A activity. Cancer Res 67: 5362–5370.
Li M, Fang X, Baker DJ, Guo L, Gao X, Wei Z et al. (2010). The ATM-p53 pathway suppresses aneuploidy-induced tumorigenesis. Proc Natl Acad Sci USA 107: 14188–14193.
Lok W, Klein RQ, Saif MW . (2010). Aurora kinase inhibitors as anti-cancer therapy. Anticancer Drugs 21: 339–350.
Maliga Z, Mitchison TJ . (2006). Small-molecule and mutational analysis of allosteric Eg5 inhibition by monastrol. BMC Chem Biol 6: 2.
Manchado E, Guillamot M, de Carcer G, Eguren M, Trickey M, Garcia-Higuera I et al. (2010). Targeting mitotic exit leads to tumor regression in vivo: modulation by Cdk1, Mastl, and the PP2A/B55alpha,delta phosphatase. Cancer Cell 18: 641–654.
Manfredi JJ, Horwitz SB . (1984). Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther 25: 83–125.
Marcus AI, Peters U, Thomas SL, Garrett S, Zelnak A, Kapoor TM et al. (2005). Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells. J Biol Chem 280: 11569–11577.
Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ . (1999). Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 286: 971–974.
Mazumdar M, Lee JH, Sengupta K, Ried T, Rane S, Misteli T . (2006). Tumor formation via loss of a molecular motor protein. Curr Biol 16: 1559–1564.
Meraldi P, Honda R, Nigg EA . (2002). Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells. EMBO J 21: 483–492.
Michel L, Diaz-Rodriguez E, Narayan G, Hernando E, Murty VV, Benezra R . (2004). Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. Proc Natl Acad Sci USA 101: 4459–4464.
Michel LS, Liberal V, Chatterjee A, Kirchwegger R, Pasche B, Gerald W et al. (2001). MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 409: 355–359.
Nigg EA . (2002). Centrosome aberrations: cause or consequence of cancer progression? Nat Rev Cancer 2: 815–825.
Oke A, Pearce D, Wilkinson RW, Crafter C, Odedra R, Cavenagh J et al. (2009). AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res 69: 4150–4158.
Olaharski AJ, Sotelo R, Solorza-Luna G, Gonsebatt ME, Guzman P, Mohar A et al. (2006). Tetraploidy and chromosomal instability are early events during cervical carcinogenesis. Carcinogenesis 27: 337–343.
Pihan GA, Purohit A, Wallace J, Malhotra R, Liotta L, Doxsey SJ . (2001). Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression. Cancer Res 61: 2212–2219.
Quintyne NJ, Reing JE, Hoffelder DR, Gollin SM, Saunders WS . (2005). Spindle multipolarity is prevented by centrosomal clustering. Science 307: 127–129.
Rieder CL, Maiato H . (2004). Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 7: 637–651.
Rieder CL, Medema RH . (2009). No way out for tumor cells. Cancer Cell 16: 274–275.
Ring D, Hubble R, Kirschner M . (1982). Mitosis in a cell with multiple centrioles. J Cell Biol 94: 549–556.
Rowinsky EK, Donehower RC, Jones RJ, Tucker RW . (1988). Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 48: 4093–4100.
Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC . (1993). Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20: 1–15.
Rusan NM, Peifer M . (2008). Original CIN: reviewing roles for APC in chromosome instability. J Cell Biol 181: 719–726.
Sakowicz R, Finer JT, Beraud C, Crompton A, Lewis E, Fritsch A et al. (2004). Antitumor activity of a kinesin inhibitor. Cancer Res 64: 3276–3280.
Santaguida S, Tighe A, D'Alise AM, Taylor SS, Musacchio A . (2010). Dissecting the role of MPS1 in chromosome biorientation and the spindle checkpoint through the small molecule inhibitor reversine. J Cell Biol 190: 73–87.
Sato N, Mizumoto K, Nakamura M, Maehara N, Minamishima YA, Nishio S et al. (2001). Correlation between centrosome abnormalities and chromosomal instability in human pancreatic cancer cells. Cancer Genet Cytogenet 126: 13–19.
Sawin KE, LeGuellec K, Philippe M, Mitchison TJ . (1992). Mitotic spindle organization by a plus-end-directed microtubule motor. Nature 359: 540–543.
Schafer-Hales K, Iaconelli J, Snyder JP, Prussia A, Nettles JH, El-Naggar A et al. (2007). Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function. Mol Cancer Ther 6: 1317–1328.
Schmidt M, Medema RH . (2006). Exploiting the compromised spindle assembly checkpoint function of tumor cells: dawn on the horizon? Cell Cycle 5: 159–163.
Schoffski P . (2009). Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 14: 559–570.
Schvartzman JM, Sotillo R, Benezra R . (2010). Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat Rev Cancer 10: 102–115.
Shi J, Orth JD, Mitchison T . (2008). Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Res 68: 3269–3276.
Shi Q, King RW . (2005). Chromosome nondisjunction yields tetraploid rather than aneuploid cells in human cell lines. Nature 437: 1038–1042.
Silkworth WT, Nardi IK, Scholl LM, Cimini D . (2009). Multipolar spindle pole coalescence is a major source of kinetochore mis-attachment and chromosome mis-segregation in cancer cells. PLoS One 4: e6564.
Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M et al. (2007). BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17: 316–322.
Stobbe CC, Park SJ, Chapman JD . (2002). The radiation hypersensitivity of cells at mitosis. Int J Radiat Biol 78: 1149–1157.
Strebhardt K, Ullrich A . (2006). Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 6: 321–330.
Tanenbaum ME, Macurek L, Janssen A, Geers EF, Alvarez-Fernandez M, Medema RH . (2009). Kif15 cooperates with eg5 to promote bipolar spindle assembly. Curr Biol 19: 1703–1711.
Tcherniuk S, van Lis R, Kozielski F, Skoufias DA . (2010). Mutations in the human kinesin Eg5 that confer resistance to monastrol and S-trityl-L-cysteine in tumor derived cell lines. Biochem Pharmacol 79: 864–872.
Terrano DT, Upreti M, Chambers TC . (2010). Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol Cell Biol 30: 640–656.
Thompson SL, Bakhoum SF, Compton DA . (2010). Mechanisms of chromosomal instability. Curr Biol 20: R285–R295.
Thompson SL, Compton DA . (2008). Examining the link between chromosomal instability and aneuploidy in human cells. J Cell Biol 180: 665–672.
Thompson SL, Compton DA . (2010). Proliferation of aneuploid human cells is limited by a p53-dependent mechanism. J Cell Biol 188: 369–381.
Torres EM, Dephoure N, Panneerselvam A, Tucker CM, Whittaker CA, Gygi SP et al. (2010). Identification of aneuploidy-tolerating mutations. Cell 143: 71–83.
Torres EM, Sokolsky T, Tucker CM, Chan LY, Boselli M, Dunham MJ et al. (2007). Effects of aneuploidy on cellular physiology and cell division in haploid yeast. Science 317: 916–924.
Torres EM, Williams BR, Amon A . (2008). Aneuploidy: cells losing their balance. Genetics 179: 737–746.
Tuxen MK, Hansen SW . (1994). Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev 20: 191–214.
Uetake Y, Loncarek J, Nordberg JJ, English CN, La Terra S, Khodjakov A et al. (2007). Cell cycle progression and de novo centriole assembly after centrosomal removal in untransformed human cells. J Cell Biol 176: 173–182.
Uetake Y, Sluder G . (2004). Cell cycle progression after cleavage failure: mammalian somatic cells do not possess a ‘tetraploidy checkpoint’. J Cell Biol 165: 609–615.
Uetake Y, Sluder G . (2010). Prolonged prometaphase blocks daughter cell proliferation despite normal completion of mitosis. Curr Biol 20: 1666–1671.
Vader G, Medema RH, Lens SM . (2006). The chromosomal passenger complex: guiding aurora-B through mitosis. J Cell Biol 173: 833–837.
Vanneste D, Takagi M, Imamoto N, Vernos I . (2009). The role of Hklp2 in the stabilization and maintenance of spindle bipolarity. Curr Biol 19: 1712–1717.
Vantieghem A, Xu Y, Assefa Z, Piette J, Vandenheede JR, Merlevede W et al. (2002). Phosphorylation of Bcl-2 in G2/M phase-arrested cells following photodynamic therapy with hypericin involves a CDK1-mediated signal and delays the onset of apoptosis. J Biol Chem 277: 37718–37731.
Vitale I, Senovilla L, Galluzzi L, Criollo A, Vivet S, Castedo M et al. (2008). Chk1 inhibition activates p53 through p38 MAPK in tetraploid cancer cells. Cell Cycle 7: 1956–1961.
Wang Z, Cummins JM, Shen D, Cahill DP, Jallepalli PV, Wang TL et al. (2004). Three classes of genes mutated in colorectal cancers with chromosomal instability. Cancer Res 64: 2998–3001.
Weaver BA, Cleveland DW . (2006). Does aneuploidy cause cancer? Curr Opin Cell Biol 18: 658–667.
Weaver BA, Silk AD, Montagna C, Verdier-Pinard P, Cleveland DW . (2007). Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 11: 25–36.
Westra A, Dewey WC . (1971). Variation in sensitivity to heat shock during the cell-cycle of Chinese hamster cells in vitro. Int J Radiat Biol Relat Stud Phys Chem Med 19: 467–477.
Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C et al. (2007). AZD1152, a selective inhibitor of aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 13: 3682–3688.
Williams BR, Prabhu VR, Hunter KE, Glazier CM, Whittaker CA, Housman DE et al. (2008). Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells. Science 322: 703–709.
Wong C, Stearns T . (2005). Mammalian cells lack checkpoints for tetraploidy, aberrant centrosome number, and cytokinesis failure. BMC Cell Biol 6: 6.
Wood KW, Lad L, Luo L, Qian X, Knight SD, Nevins N et al. (2010). Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. Proc Natl Acad Sci USA 107: 5839–5844.
Wu L, Ma CA, Zhao Y, Jain A . (2011). Aurora B interacts with NIR-p53, leading to p53 phosphorylation in its DNA-binding domain and subsequent functional suppression. J Biol Chem 286: 2236–2244.
Yang Z, Loncarek J, Khodjakov A, Rieder CL . (2008). Extra centrosomes and/or chromosomes prolong mitosis in human cells. Nat Cell Biol 10: 748–751.
Yao X, Abrieu A, Zheng Y, Sullivan KF, Cleveland DW . (2000). CENP-E forms a link between attachment of spindle microtubules to kinetochores and the mitotic checkpoint. Nat Cell Biol 2: 484–491.
Yue QX, Liu X, Guo DA . (2010). Microtubule-binding natural products for cancer therapy. Planta Med 76: 1037–1043.
Yuen KW, Montpetit B, Hieter P . (2005). The kinetochore and cancer: what's the connection? Curr Opin Cell Biol 17: 576–582.
Zeng X, Sigoillot F, Gaur S, Choi S, Pfaff KL, Oh DC et al. (2010). Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. Cancer Cell 18: 382–395.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Janssen, A., Medema, R. Mitosis as an anti-cancer target. Oncogene 30, 2799–2809 (2011). https://doi.org/10.1038/onc.2011.30
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2011.30
Keywords
This article is cited by
-
Inhibition of Mps1 kinase enhances taxanes efficacy in castration resistant prostate cancer
Cell Death & Disease (2022)
-
MARK2 regulates chemotherapeutic responses through class IIa HDAC-YAP axis in pancreatic cancer
Oncogene (2022)
-
Advances in the study of emodin: an update on pharmacological properties and mechanistic basis
Chinese Medicine (2021)
-
PAWI-2: A novel inhibitor for eradication of cancer
Medicinal Chemistry Research (2020)
-
Cyclin-dependent kinase 1-mediated phosphorylation of SET at serine 7 is essential for its oncogenic activity
Cell Death & Disease (2019)
